(VIANEWS) – Golden Bull Limited (BTBT), Viad Corp (VVI), Paylocity Holding Corporation (PCTY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Golden Bull Limited (BTBT)
188.2% sales growth and 21.83% return on equity
Bit Digital, Inc., together with its subsidiaries, engages in the bitcoin mining business. It is also involved in the treasury management activities; and digital asset staking and digital asset mining businesses, as well as ethereum staking activities. The company was formerly known as Golden Bull Limited and changed its name to Bit Digital, Inc. in September 2020. Bit Digital, Inc. was founded in 2015 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Golden Bull Limited has a trailing twelve months EPS of $0.3.
PE Ratio
Golden Bull Limited has a trailing twelve months price to earnings ratio of 12.67. Meaning, the purchaser of the share is investing $12.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.83%.
2. Viad Corp (VVI)
25.3% sales growth and 8.6% return on equity
Viad Corp operates as an experiential leisure travel, and live events and marketing services company in the United States, Canada, the United Kingdom, the United Arab Emirates, Netherlands, and Iceland. It operates through Pursuit, Spiro, and GES Exhibitions segments. The Pursuit segment offers vertically integrated attractions and hospitality in destinations with a collection of attractions, lodges, and sightseeing tours. The GES Exhibition operates as an exhibition services company that partners with exhibition and conference organizers as a full-service provider of strategic and logistics solutions to manage the complexity of their shows. The Spiro operates experiential marketing agency that partners with brands around the world to manage and elevate their global experiential marketing activities. In addition, the company offers a collection of travel experiences in recreational attractions, food and beverage, retail, and ground transportation services. It serves event organizers and corporate brand marketers directly, as well as through a distribution channel network that include tour operators, tour wholesalers, destination management companies, and retail travel agencies. Viad Corp was founded in 1926 and is headquartered in Scottsdale, Arizona.
Earnings Per Share
As for profitability, Viad Corp has a trailing twelve months EPS of $0.15.
PE Ratio
Viad Corp has a trailing twelve months price to earnings ratio of 256.27. Meaning, the purchaser of the share is investing $256.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.6%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.9%, now sitting on 1.25B for the twelve trailing months.
Sales Growth
Viad Corp’s sales growth is 12.2% for the present quarter and 25.3% for the next.
3. Paylocity Holding Corporation (PCTY)
12.1% sales growth and 20.9% return on equity
Paylocity Holding Corporation provides cloud-based payroll and human capital management software solutions for medium-sized organizations in the United States. The company offers Payroll and Tax Services solution to simplify payroll, automate processes and manage compliance requirements within one system; expense management, on demand payment, and garnishment solutions; human capital management and employee self-service solutions, document library, compliance dashboard, and HR edge; time and attendance solution, which tracks time and attendance data, eliminating the need for manual tracking of accruals and reducing administrative tasks; schedule tracking services; and time collection devices, including kiosks, time clocks, and mobile and web applications. In addition, the company offers talent management solutions comprising recruiting and onboarding, as well as learning, performance, and compensation management; employee benefits management and third-party administrative solutions; modern workforce solutions consisting of community, premium video, survey, and peer recognition; and analytics and insights solutions covering modern workforce index, data insights, and reporting. Further, it provides implementation and training, client, and tax and regulatory services. The company's clients include for-profit and non-profit organizations across industries, including business services, financial services, healthcare, manufacturing, restaurants, retail, technology, and others. It sells its products through sales representatives. The company was founded in 1997 and is headquartered in Schaumburg, Illinois.
Earnings Per Share
As for profitability, Paylocity Holding Corporation has a trailing twelve months EPS of $3.42.
PE Ratio
Paylocity Holding Corporation has a trailing twelve months price to earnings ratio of 43.69. Meaning, the purchaser of the share is investing $43.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.2%, now sitting on 1.35B for the twelve trailing months.
Volume
Today’s last reported volume for Paylocity Holding Corporation is 284047 which is 52.95% below its average volume of 603826.
Moving Average
Paylocity Holding Corporation’s worth is higher than its 50-day moving average of $144.17 and below its 200-day moving average of $159.71.
4. Incyte Corporation (INCY)
9.9% sales growth and 15.13% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 20.32. Meaning, the purchaser of the share is investing $20.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.13%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.9%, now sitting on 3.77B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 12.1% and 11.8%, respectively.
